ITCI Annual SG&A
$409.86 M
+$51.08 M+14.24%
31 December 2023
Summary:
As of January 19, 2025, ITCI annual selling, general & administrative expenses is $409.86 million, with the most recent change of +$51.08 million (+14.24%) on December 31, 2023. During the last 3 years, it has risen by +$223.50 million (+119.93%). ITCI annual SG&A is now at all-time high.ITCI Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ITCI Quarterly SG&A
$132.10 M
+$10.53 M+8.66%
30 September 2024
Summary:
As of January 19, 2025, ITCI quarterly selling, general & administrative expenses is $132.10 million, with the most recent change of +$10.53 million (+8.66%) on September 30, 2024. Over the past year, it has increased by +$26.89 million (+25.56%). ITCI quarterly SG&A is now at all-time high.ITCI Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ITCI TTM SG&A
-$6.57 B
-$86.37 M-1.33%
30 September 2024
Summary:
As of January 19, 2025, ITCI TTM selling, general & administrative expenses is -$6.57 billion, with the most recent change of -$86.37 million (-1.33%) on September 30, 2024. Over the past year, it has dropped by -$6.97 billion (-1744.21%). ITCI TTM SG&A is now -15286283.72% below its all-time high of $471.48 million, reached on September 30, 2024.ITCI TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ITCI Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +14.2% | +25.6% | -1744.2% |
| 3 y3 years | +119.9% | +25.6% | -1744.2% |
| 5 y5 years | +1261.7% | +25.6% | -1744.2% |
ITCI Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +50.4% | at high | +75.1% | -49.2% | at low |
| 5 y | 5-year | at high | +531.1% | at high | +480.3% | -151.7% | at low |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% | <-9999.0% | at low |
Intra-Cellular Therapies Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $132.10 M(+8.7%) | $471.48 M(+6.0%) |
| June 2024 | - | $121.57 M(+7.5%) | $444.59 M(+4.8%) |
| Mar 2024 | - | $113.08 M(+8.0%) | $424.03 M(+3.5%) |
| Dec 2023 | $409.86 M(+14.2%) | $104.72 M(-0.5%) | $409.86 M(+2.5%) |
| Sept 2023 | - | $105.21 M(+4.2%) | $399.77 M(+4.4%) |
| June 2023 | - | $101.01 M(+2.1%) | $382.94 M(+0.2%) |
| Mar 2023 | - | $98.92 M(+4.5%) | $382.25 M(+6.5%) |
| Dec 2022 | $358.78 M(+31.6%) | $94.63 M(+7.1%) | $358.78 M(+4.3%) |
| Sept 2022 | - | $88.38 M(-11.9%) | $343.83 M(+5.5%) |
| June 2022 | - | $100.32 M(+32.9%) | $325.95 M(+10.3%) |
| Mar 2022 | - | $75.46 M(-5.3%) | $295.49 M(+8.4%) |
| Dec 2021 | $272.61 M(+46.3%) | $79.68 M(+13.0%) | $272.61 M(+8.5%) |
| Sept 2021 | - | $70.50 M(+0.9%) | $251.28 M(+7.7%) |
| June 2021 | - | $69.85 M(+32.8%) | $233.26 M(+13.9%) |
| Mar 2021 | - | $52.58 M(-9.9%) | $204.85 M(+9.9%) |
| Dec 2020 | $186.36 M(+186.9%) | $58.35 M(+11.2%) | $186.36 M(+23.6%) |
| Sept 2020 | - | $52.47 M(+26.6%) | $150.78 M(+33.0%) |
| June 2020 | - | $41.45 M(+21.6%) | $113.34 M(+29.8%) |
| Mar 2020 | - | $34.10 M(+49.8%) | $87.34 M(+34.5%) |
| Dec 2019 | $64.95 M(+115.8%) | $22.76 M(+51.4%) | $64.95 M(+26.8%) |
| Sept 2019 | - | $15.04 M(-2.6%) | $51.20 M(+16.0%) |
| June 2019 | - | $15.44 M(+31.9%) | $44.14 M(+24.6%) |
| Mar 2019 | - | $11.71 M(+29.8%) | $35.42 M(+17.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | $30.10 M(+27.2%) | $9.02 M(+13.1%) | $30.10 M(+12.0%) |
| Sept 2018 | - | $7.97 M(+18.5%) | $26.87 M(+11.0%) |
| June 2018 | - | $6.73 M(+5.5%) | $24.21 M(+2.0%) |
| Mar 2018 | - | $6.38 M(+10.3%) | $23.74 M(+0.3%) |
| Dec 2017 | $23.67 M(-4.4%) | $5.78 M(+8.8%) | $23.67 M(-4.7%) |
| Sept 2017 | - | $5.32 M(-15.0%) | $24.83 M(-3.7%) |
| June 2017 | - | $6.25 M(-0.9%) | $25.79 M(-0.8%) |
| Mar 2017 | - | $6.31 M(-9.2%) | $26.00 M(+5.0%) |
| Dec 2016 | $24.76 M(+36.1%) | $6.95 M(+10.9%) | $24.76 M(+1.7%) |
| Sept 2016 | - | $6.27 M(-3.1%) | $24.34 M(+10.8%) |
| June 2016 | - | $6.47 M(+27.8%) | $21.97 M(+12.8%) |
| Mar 2016 | - | $5.06 M(-22.5%) | $19.48 M(+7.1%) |
| Dec 2015 | $18.19 M(+75.9%) | $6.54 M(+68.0%) | $18.19 M(+18.3%) |
| Sept 2015 | - | $3.89 M(-2.4%) | $15.37 M(+9.3%) |
| June 2015 | - | $3.99 M(+5.7%) | $14.06 M(+15.3%) |
| Mar 2015 | - | $3.77 M(+1.3%) | $12.20 M(+18.0%) |
| Dec 2014 | $10.34 M(+73.0%) | $3.72 M(+44.2%) | $10.34 M(+10.6%) |
| Sept 2014 | - | $2.58 M(+21.7%) | $9.35 M(+16.0%) |
| June 2014 | - | $2.12 M(+10.9%) | $8.06 M(+35.5%) |
| Mar 2014 | - | $1.91 M(-29.9%) | $5.95 M(+47.4%) |
| Dec 2013 | $5.98 M(+48.1%) | $2.73 M(+110.8%) | $4.04 M(+209.0%) |
| Sept 2013 | - | $1.30 M(>+9900.0%) | $1.31 M(>+9900.0%) |
| June 2013 | - | $10.80 K | $10.80 K |
| Dec 2012 | $4.03 M | - | - |
FAQ
- What is Intra-Cellular Therapies annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Intra-Cellular Therapies?
- What is Intra-Cellular Therapies annual SG&A year-on-year change?
- What is Intra-Cellular Therapies quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Intra-Cellular Therapies?
- What is Intra-Cellular Therapies quarterly SG&A year-on-year change?
- What is Intra-Cellular Therapies TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Intra-Cellular Therapies?
- What is Intra-Cellular Therapies TTM SG&A year-on-year change?
What is Intra-Cellular Therapies annual selling, general & administrative expenses?
The current annual SG&A of ITCI is $409.86 M
What is the all time high annual SG&A for Intra-Cellular Therapies?
Intra-Cellular Therapies all-time high annual selling, general & administrative expenses is $409.86 M
What is Intra-Cellular Therapies annual SG&A year-on-year change?
Over the past year, ITCI annual selling, general & administrative expenses has changed by +$51.08 M (+14.24%)
What is Intra-Cellular Therapies quarterly selling, general & administrative expenses?
The current quarterly SG&A of ITCI is $132.10 M
What is the all time high quarterly SG&A for Intra-Cellular Therapies?
Intra-Cellular Therapies all-time high quarterly selling, general & administrative expenses is $132.10 M
What is Intra-Cellular Therapies quarterly SG&A year-on-year change?
Over the past year, ITCI quarterly selling, general & administrative expenses has changed by +$26.89 M (+25.56%)
What is Intra-Cellular Therapies TTM selling, general & administrative expenses?
The current TTM SG&A of ITCI is -$6.57 B
What is the all time high TTM SG&A for Intra-Cellular Therapies?
Intra-Cellular Therapies all-time high TTM selling, general & administrative expenses is $471.48 M
What is Intra-Cellular Therapies TTM SG&A year-on-year change?
Over the past year, ITCI TTM selling, general & administrative expenses has changed by -$6.97 B (-1744.21%)